Original Article
Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumor cells

https://doi.org/10.1016/j.prp.2009.12.006Get rights and content

Abstract

Our aim was to compare the HER-2 and hormone receptor status between primary tumor (PT) and sentinel node (SN) metastases in breast cancer.

We analyzed 65 PTs with 42 macrometastases, 18 micrometastases, and 5 ITCs for the HER-2 amplification status and for the hormone receptor status.

In HER-2-positive PTs, 26 of 29 metastases were HER-2-positive, including all six analyzed micrometastases and ITCs. Three macrometastases were HER-2-negative. In HER-2-negative PTs, 35 of 36 metastases were HER-2-negative. A low-grade HER-2 amplification was detected in one micrometastasis.

A full concordance between the PT and SN metastases in both HER-2 amplification and ER and PR status was observed in 40 of 56 (71%) cases. These 40 fully concordant cases included 27 macrometastatic, 9 micrometastatic, and 4 ITC-cases.

The concordance in HER-2, ER, and PR was high between the PT and their SN metastases. However, the concordance may be remarkably lower when analyzed simultaneously for all three predictive factors.

Introduction

Sentinel node (SN) biopsy has largely replaced axillary lymph node dissection in lymphatic staging of early breast cancer. This technique allows a thorough examination of only a few lymph nodes, as well as the application of serial sectioning of excised lymphatic tissue followed by immunohistochemistry (IHC). As a consequence, small cancerous deposits are frequently detected, and a new dimension of regional lymph node metastases has been identified, micrometastases and isolated tumor cells (ITCs) [1]. The clinical significance of micrometastases and ITCs is currently unclear, and studies addressing their prognostic impact are controversial. It has been speculated that some ITCs may constitute tissue dislocated after a tissue needle biopsy or tissue handling rather than being true metastatic deposits [2], [3].

Overexpression of the HER-2 (c-erb B2) tyrosine kinase in breast cancer is usually associated with aggressive tumor features and poor outcome [4]. The outcome of HER-2-positive breast cancer has now improved considerably due to trastuzumab and other HER-2-targeting therapies [5], [6], [7]. The HER-2 status is usually analyzed from the primary breast tumor, which raises the question of whether the HER-2-status of the primary tumor reliably reflects that of cancer metastases. In general, the concordance of the HER-2 status between the primary tumor and ipsilateral axillary lymph node metastases is high, ranging from 78% to 90% [8], [9], [10], [11]. Similarly, a high concordance in the estrogen receptor (ER) and progesterone receptor (PR) status, ranging from 79% to 90%, has been reported between primary tumors and axillary lymph node metastases [12], [13], [14], [15], [16], [17], [18]. However, the majority of the LN metastases examined in previous studies are macrometastases obtained from axillary lymph node dissection specimens, and the concordance between the primary tumor HER-2 and steroid hormone receptor expression levels and those of lymph node micrometastases and ITCs is not known.

The aim of the present study was to compare the HER-2, ER, and PR status of the primary breast tumors with that of SN micrometastases and ITCs to elucidate the biological significance of lymph node micrometastases and ITCs.

Section snippets

Patients and methods

A total of 1652 breast cancer patients underwent an SN biopsy between February 2001 and July 2005 at the Breast Surgery Unit of Helsinki University Central Hospital, Finland. The study patients were selected from a prospectively collected database, established for investigating the SN biopsy technique.

The HER-2 CISH-positive study group

Altogether 39 SN-positive patients were selected, all with primary tumors with HER-2 amplification in chromogenic in situ hybridization (CISH). All cases with micrometastases (n=6) or ITCs (n=9)

Immunohistochemistry

The status for ER was analyzed both in the PT and the SN metastases by routine IHC using clone Ncl-Er-6F11 with a dilution of 1:50 (Novocastra Laboratories Ltd., Newcastle upon Tyne, United Kingdom). PR was analyzed by clone PGR 636, dilution 1:100 by DAKO (Cytomation, Glostrup, Denmark), in the primary tumor and the SN metastasis. Positive staining in IHC was defined as at least over 10% nuclear staining for ER and PR. The proliferation index Ki-67 was analyzed in the PT with clone MIB-1 by

The concordance in HER-2 amplification status between PT and SN metastases

In the HER-2 CISH-positive PTs, altogether 26 (90%) of the analyzed 29 metastases showed a low or a high level of HER-2 gene amplification in CISH. Three cases were negative. All these three discordant cases were macrometastases. The amplification level of HER-2 in the SN metastases is presented in Fig. 1.

In the 23 macrometastases, the amplification level was fully identical when compared with the PT in 16 (70%) cases, lower in 4 (17%) cases, and negative in 3 (13%) cases. None of the

Discussion

To the best of our knowledge, this is the first study to evaluate the concordance of the HER-2 status between primary breast cancer and SN micrometastases or ITCs. Among the HER-2-positive PTs, all the SN micrometastases and ITCs studied were also HER-2-positive. The high HER-2 gene amplification level in the three ITC-cases suggests that ITCs may represent metastatic cells with a potential for aggressive behavior. We are aware of the fact that the number of cases examined in this study is very

Conclusions

The concordance in HER-2, ER, and PR was high between the PTs and their SN metastases, as well as even micrometastases and ITCs. However, this concordance may be remarkably lower, when analyzed simultaneously for all three predictive factors. The high HER-2 gene amplification level in the three analyzed ITC-cases could imply that ITCs may represent metastatic cells with a potential for aggressive behavior.

Conflicts of interest

None declared.

References (45)

  • J.S. Ross et al.

    HER-2/neu (c- erbB2) gene and protein in breast cancer

    Am. J. Clin. Pathol.

    (1999)
  • M.J. Piccart-Gebhart et al.

    Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer

    NEJM

    (2005)
  • H. Joensuu et al.

    Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

    NEJM

    (2006)
  • C. Geyer et al.

    Lapatinib plus Capecitabine for HER-2-Positive advanced breast cancer

    NEJM

    (2006)
  • A.V. Bassarova et al.

    Simultaneous bilateral breast carcinomas: a category with frequent coexpression of HER-2 and ER-alfa, high Ki-67 and bcl-2, and low p53

    Int. J. Surg. Pathol.

    (2005)
  • M. Tanner et al.

    Amplification of HER-2 neu and topoisomerase II α in primary and metastatic breast cancer

    Cancer Res.

    (2001)
  • G.A. Niehans et al.

    Stability of HER-2 expression over time and multiple metastatic sites

    J. Natl. Cancer Inst.

    (1993)
  • S.M. Edgerton et al.

    CerB-2 (HER-2) and breast cancer progression

    Appl. Imm. Mol. Morph.

    (2003)
  • J.L. Hoehn et al.

    Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast

    Ann. Surg.

    (1979)
  • C. Kamby et al.

    Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence

    Br. J. Cancer

    (1989)
  • J.A. Butler et al.

    Value of measuring hormone receptor levels of regional metastatic carcinoma of the breast

    Arch. Surg.

    (1989)
  • J. Andersen et al.

    Relationship between estrogen receptor status in the primary tumour and its regional and distant metastases. An immunohistochemical study in human breast cancer

    Acta Oncol.

    (1988)
  • Cited by (20)

    • HER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese women

      2016, Pathology Research and Practice
      Citation Excerpt :

      HER-2 is the most promising biological marker in terms of predictive value for breast cancer treatment. Previous studies demonstrated a high level of consistency in the HER-2 expression between primary tumors and metastatic sites [9–13]. However, there were also some reports that demonstrated discordance of HER-2 status between primary tumors and metastatic sites [14–22].

    • Detecting Tumor Metastases: The Road to Therapy Starts Here

      2016, Advances in Cancer Research
      Citation Excerpt :

      A study of elevated HER2 levels, a protein-based biomarker, detected in tissue specimens of primary tumors and axillary lymph node or distant metastases has been shown to correlate in several clinical studies (Brufsky et al., 2011; Kuba et al., 2014; Shao et al., 2011). In contrast, multiple studies indicate that HER2-positive metastases with negative primary tumors are more frequent (Dieci et al., 2013; Jensen, Knoop, Ewertz, & Laenkholm, 2012; Strien, Leidenius, von Smitten, & Heikkila, 2010; Xiao, Gong, Han, Gonzalez-Angulo, & Sneige, 2011). Thus, Rossi et al. concluded that this phenomenon could be correlated with enhanced tumor aggressiveness or with an underestimation of HER2 protein overexpression in the primary tumor by the pathologist (Rossi et al., 2012).

    • Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared with Synchronous Axillary Metastases or Recurrent Metastatic Disease

      2015, Clinical Breast Cancer
      Citation Excerpt :

      Changes in ER and particularly in PR are observed in locoregional and in distant metastases, which reached a rate of 10% to 30% for ER and 20% to 50% for PR. The loss of PR was particularly frequent, which suggested the emergence of a different cancer phenotype (Tables 1 and 2).7-11,14-21 The frequent shift of ER/PR status might be due to selection/expansion of a different clone of cancer cells due to genetic or epigenetic mechanisms.

    View all citing articles on Scopus
    View full text